Potassium Carbonate → 5-amino-3-[(2R,3R,5S)-5-(1-hydroxypropyl)-3-prop-2-enyloxolan-2-yl]-6H-[1,3]thiazolo[4,5-d]pyrimidine-2,7-dione
반응식
C([O:9][CH:10]([C@@H:13]1[CH2:17][C@@H:16]([CH2:18][CH:19]=[CH2:20])[C@H:15]([N:21]2[C:25]3[N:26]=[C:27]([NH2:31])[NH:28][C:29](=[O:30])[C:24]=3[S:23][C:22]2=[O:32])[O:14]1)[CH2:11][CH3:12])(=O)C1C=CC=CC=1.C([O-])([O-])=O.[K+].[K+].[NH4+].[Cl-]>CO>[CH2:18]([C@@H:16]1[CH2:17][C@@H:13]([CH:10]([OH:9])[CH2:11][CH3:12])[O:14][C@H:15]1[N:21]1[C:25]2[N:26]=[C:27]([NH2:31])[NH:28][C:29](=[O:30])[C:24]=2[S:23][C:22]1=[O:32])[CH:19]=[CH2:20]참가 물질
반응물 3
생성물 1
시약·촉매·용매 1
실험 절차
To a solution of 1-[(2S,4R,5R)-4-allyl-5-(5-amino-2,7-dioxo-6H-thiazolo[4,5-d]pyrimidin-3-yl)tetrahydrofuran-2-yl]propyl benzoate (compound 26f, 800 mg, 1.75 mmol) in methanol (25 mL) was added K2CO3 (483 mg, 3.5 mmol). After being stirred at room temperature for 12 hours, the reaction was diluted by saturated NH4Cl solution and extracted with DCM. The organic layers were combined and concentrated in vacuo. The residue was purified by preparative HPLC to afford 200 mg of 3-[(2R,3R,5S)-3-allyl-5-(1-hydroxypropyl)tetrahydrofuran-2-yl]-5-amino-6H-thiazolo[4,5-d]pyrimidine-2,7-dione (Example 26). 100 mg of Example 26 was further separated by supercritical fluid chromatography (SFC) to afford 32.0 mg of Example 26-A and 30.8 mg of Example 26-B as white solid.
후처리
- extractionextracted with DCM
- concentrationconcentrated in vacuo
- customThe residue was purified by preparative HPLC
출처 및 근거
- ORD 기록
- ord-fbbab511873f42c28a60ff46bb78a2a8
- 출처 데이터셋
- uspto-grants-2016_09
- 특허 번호
- US09441008B2
반응 노트
불러오는 중…